3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
4
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
41
Recurrence
9
Neoplasms, Plasma Cell
5
Smoldering Multiple Myeloma
3
Waldenstrom Macroglobulinemia
1
Neoplasms
1
Lymphoma, Large B-Cell, Diffuse
1
Interventions
Rituximab
6
ibrutinib
4
venetoclax
3
acalabrutinib
3
zanubrutinib
2
pirtobrutinib
2
fludarabine phosphate
2
Whole-Body Irradiation
2
Sirolimus
2
Mycophenolic Acid
2
Melphalan
2
Cyclophosphamide
2
Bortezomib
2
Bendamustine Hydrochloride
2
selinexor
1
loncastuximab tesirine
1
ixazomib
1
carfilzomib
1
Valganciclovir
1
Valacyclovir
1
Therapeutics
1
Tacrolimus
1
Polymerase Chain Reaction
1
Pharmacogenomic Testing
1
Peripheral Blood Stem Cell Transplantation
1
Nivolumab
1
Methotrexate
1
Lenalidomide
1
Ganciclovir
1
Foscarnet
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Waldenstrom Macroglobulinemia
×
carfilzomib
×
Clear all
NCT04263480
2026-05-12
CZAR-1
University of Ulm
Phase 2
Active not recruiting
99 enrolled